Phase 1/2 Trial for CRG-150, a New Approach to Immunotherapy

CRG-150 is entering first-in-human testing as an unconventional immunotherapy for patients with relapsed or refra9ctory metastatic prostate cancer and other solid tumors.
The autologous, CRISPR-edited cell therapy targets steroid receptor coactivator 3, or SRC-3, in regulatory T cells. Tregs help maintain immune tolerance but can suppress antitumor immunity in prostate cancer. By disrupting SRC-3, CRG-150 aims to reprogram these cells and stimulate a stronger local antitumor immune response.
Preclinical studies in immune-intact prostate cancer models reported tumor control without an apparent systemic autoimmune phenotype.
The Phase 1/2a trial will assess CRG-150 in heavily pretreated patients with metastatic prostate cancer, alongside breast-cancer cohorts. A key feature is the planned absence of lymphodepleting chemotherapy before infusion.
For prostate cancer, the most important early results will not simply be PSA declines or radiographic responses. Investigators will need to show that CRG-150 survives in patients, reaches the tumor, alters immune-cell activity, and produces durable clinical benefit.
Clinical trial.